This series of four short interviews provides important insights for the use of F-18 tracers; transitioning from SPECT to PET imaging and changes needed for F-18 tracers versus other cardiac PET tracers, the importance of MBF and understanding how it will be impacted by a retained tracer, clinical data on F-18 flurpiridaz and the existing challenges of establishing cardiac PET centers around the world.

This activity will provide important insights from the CME symposium, Cardiovascular PET: Moving into F-18 Myocardial Perfusion Imaging and improve understanding of the clinical value of PET, the importance and approaches to incorporating it into everyday clinical practice and the role F-18 labeled tracers may play worldwide in the future.

• Define the clinical value of cardiac PET across different clinical scenarios
• Describe the added value of MBF and MBFR
• Analyze recent clinical trial data and the impact of new F-18 tracers for cardiac PET
• Identify important factors impacting the growth of cardiac PET worldwide

The American Society of Nuclear Cardiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physicians: The American Society of Nuclear Cardiology designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. 

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

if you require a Certificate of Participation for this activity, please contact info@asnc.org.

As an accredited provider of the Accreditation Council for Continuing Medical Education (ACCME), The American Society of Nuclear Cardiology (ASNC) adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. In compliance with these standards, it is ASNC’s policy to ensure balance, independence, objectivity, and scientific merit in all of its educational activities through the disclosure of relevant financial relationship with ineligible companies and mitigation of conflicts of interest. The financial interest or relationships requiring disclosure are outlined in ASNC’s CME Conflict of Interest Policy. All planners, reviewers, and presenters involved with this activity were required to disclose all financial relationships.

The American Society of Nuclear Cardiology has reviewed this activity’s faculty disclosures and mitigated or managed all identified conflicts of interest.

The following planners, presenters, peer reviewers, and staff reported no financial relationships:
Matthew Harinstein, MD (Reviewer)
Linda Giering, PhD (ASNC staff)
Wendy Passerell (ASNC staff) 

The following planners, presenters, peer reviewers, staff reported financial relationships:
Mouaz Al-Mallah, MD: Research Grant – Siemens; Consultant – Phillips, Jubilant, Pfizer
Timothy Bateman, MD: Research Grants – Bracco, GEHC, Spectrum Dynamics; Consultant – GEHC, Synektik; Ownership - CVIT
Panithaya Chareonthaitawee, MD: Consultant – Clario, Ionetix; Royalty – UpToDate
Marcelo Di Carli, MD: Research support – Gilead Sciences, Amgen; Consultant – MedTrace, Sanofi
Gary Heller, MD, PhD: Advisory Board – Molecular Imaging Services, GE HealthCare